counts occurred by day 15 in the 5-day (-2.5 [2.48]) and 3-day cohorts (-2.5 [2.22]) that continued up to day 57 (-3.9 [2.00] and -3.4 [1.75], respectively) (Figure 2) . Even with small participant numbers, consistency in AK clearance among subgroups was noted.
All 63 participants who had 100% clearance at day 57 in the Phase 2 study were included in the Recurrence Follow-up Set. Based on Kaplan-Meier analysis, at 12 months post-day 57, recurrence rates for the proportion of 5 day cohort participants were lower than the 3-day cohort (57% [95% CI, 41, 73] vs 70% [95% CI, 51, 87]). Most recurrence occurred within 6 months post-day 57.
Safety
In the Phase 1 study, no TEAEs were treatment-related, severe, or resulted in withdrawal from the study or treatment. There were no deaths or SAEs. No clinically significant changes in laboratory tests, vital signs, physical examinations, or electrocardiograms were reported. Application-site symptoms, collected separately from AEs, were mostly transient mild pruritus, and less frequently stinging/burning sensation. These were observed predominantly in Cohorts 3/4; all resolved without treatment.
In the Phase 2 study, all participants completed treatment and follow-up to day 57, and both regimens were well tolerated. There were no deaths, SAEs, or discontinuations due to treatment. Twelve of 168 participants (7%) had treatmentrelated AEs: 9 (11%) in the 5-day cohort and 3 (4%) in the 3-day cohort. Treatment-related AEs were mostly mild, transient application-site pruritus and application-site pain that resolved spontaneously. Three participants reported four treatmentrelated non-specific systemic AEs: transient mild-to-moderate dizziness and mild headache. One participant reported mild hair darkening near the treatment area, and another was
